

## AMENDMENTS TO THE CLAIMS

---

**Claims 1 and 2** (previously cancelled)

**Claim 3** (currently amended)

The method of claim 18, in which the ~~estradiol derivative is~~ contains 17 $\beta$ -estradiol.

**Claim 4** (currently amended)

The method of claim 18, in which the ~~estradiol derivative is~~ contains estradiol valerate.

**Claim 5** (currently amended)

The method of claim 18, in which the ~~estradiol derivative is~~ contains conjugated equine estrogens.

**Claim 6** (currently amended)

The method of claim 18, in which the ~~estradiol derivative is present in an amount~~ of composition contains from 0.3 to 3 mg per unitary of estrogenic compound per daily dose.


**Claim 7** (currently amended)

The method of claim 18 in which ~~estradiol is present in the free form in an amount~~ the composition contains from 0.5 to 1.5 mg per unitary of free estradiol per daily dose.

**Claim 8 (currently amended)**

The method of claim ~~15~~ 18, in which ~~estradiol valerate is present in an amount of~~  
the composition contains from 1.5 to 2 mg per unitary of an estradiol ester per daily  
dose.

**Claim 9 (currently amended)**



The method of claim ~~5~~ 18, in which composition contains from conjugated equine  
~~estrogen is present in an amount of 0.312 to 0.625 mg per unitary~~ of conjugated equine  
estrogens per daily dose.

**Claim 10 (previously cancelled)**

**Claims 11 and 12 (currently cancelled)**

**Claim 13 (currently amended)**

The method composition of claim ~~11~~ 18, in which the composition contains from  
~~nomegestrol acetate is present in an amount of 0.625 to 1.25 mg per unitary~~ daily dose of  
nomegestrol acetate.

**Claims 14 to 17 (previously cancelled)**

**Claim 18** (currently amended)

A method of preventing estrogen deficiencies in menopausal women ~~comprising~~ consisting in continuously orally administering without interruption to menopausal women in need thereof ~~an amount of~~ a composition containing from 0.3 to 3 mg of an estrogenic compound ~~estradiol derivative~~ selected from the group consisting of free estradiol, estradiol esters, 17 $\beta$ -estradiol, esterified 17 $\beta$ -estradiol and conjugated equine estrogens and from 0.3 to 1.25 mg of nomegestrol acetate per daily dose ~~or one of its~~ esters.

**Claim 19** (currently amended)

A method of preventing osteoporosis ~~and cardiovascular disorders~~ in menopausal women ~~comprising~~ consisting in continuously orally administering without interruption to menopausal women in need thereof ~~an amount of~~ a composition of 0.3 to 3 mg of an estrogenic compound ~~estradiol derivative~~ selected from the group consisting of free estradiol, estradiol esters 17 $\beta$ -estradiol, esterified 17 $\beta$ -estradiol and conjugated equine estrogens and from 0.3 to 1.25 mg of nomegestrol acetate per daily dose ~~or one of its~~ esters ~~sufficient to prevent osteoporosis and cardiovascular disorders.~~

Prevent  
Osteo  
Cardiovascular


**Claim 20** (currently amended)

The method of claim 19 in which the ~~estradiol derivative~~ is compositon contains 17 $\beta$ -estradiol.

**Claim 21 (currently amended)**

The method of claim 19 in which the composition contains estradiol derivative is estradiol valerate.

**Claim 22 (currently amended)**



The method of claim 19, in which the composition contains ~~estradiol derivative~~ equine estrogen is present in an amount ranging from 0.3 to 3 mg ~~per unitary~~ of estrogenic compound per daily dose.

**Claim 23 (currently amended)**

The method of claim 19, in which the ~~estradiol derivative is~~ composition contains conjugated equine estrogens.

**Claim 24 (currently amended)**

The method of claim ~~19~~ 18, in which the composition contains from estradiol derivative is present in an amount of 0.3 to 3 mg of estrogenic compound per daily ~~per unitary~~ dose.


**Claim 25 (currently amended)**

The method of claim 19 in which the composition contains from ~~estradiol is~~ present in the free form in an amount of 0.5 to 1.5 mg of free estradiol per unitary daily dose.

**Claim 26 (currently amended)**

The method of claim 19 in which composition contains from ~~estradiol valerate~~ is ~~present in an amount of~~ 1.5 to 2 mg of an estradiol per daily unitary dose.

**Claim 27 (currently amended)**

The method of claim ~~18~~ 19, in which the composition contains from ~~conjugated~~ equine estrogen is ~~present in an amount of~~ 0.312 to 0.625 mg of conjugated equine estrogens per unitary daily dose.

**Claims 28 and 29 (currently cancelled)**

**Claim 30 (currently amended)**

The method of claim 19, in which the composition contains from ~~norgestrel~~ acetate is ~~present in an amount of~~ 0.625 to 1.25 mg of norgestrel acetate per unitary dose.

---

**Claim 31** (currently added)

A pharmaceutical composition for hormone replacement therapy, said composition being in oral administrable form and comprising, in combination, 0.3 to 3 mg of an estrogenic compound selected from the group consisting of free estradiol or esterified estradiol and 0.3 to 1.25 mg of nomegestrol acetate.

**Claim 32** (currently added)

A pharmaceutical composition for hormone replacement therapy, said composition being in oral administrable form and comprising, in combinatino, 0.3 to 3 mg of conjugated equine estrogens and 0.3 to 1.25 mg of nomegestrol acetate.